VRCA (Verrica Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena

VRCA (Verrica Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

Mkt Cap$56M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$31M

Net Income (TTM)-$26M

EPS (TTM)-$3.45

Free Cash Flow (TTM)-$29M

Gross Margin91.9%

Op. Margin-53.2%

Net Margin-84.4%

FCF Margin-94.4%

P/S Ratio (TTM)1.8x

P/E Ratio (TTM)—

YoY Rev Growth+234.7%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$68K	-$3M	-$6M
Q1 23	$37K	-$31K	-$7M
Q2 23	$182K	$46K	-$12M
Q3 23	$3M	$3M	-$24M
Q4 23	$2M	-$19M	-$23M
Q1 24	$4M	$3M	-$19M
Q2 24	$5M	$5M	-$15M
Q3 24	-$2M	-$2M	-$21M
Q4 24	$344K	-$281K	-$11M
Q1 25	$3M	$3M	-$8M
Q2 25	$13M	$12M	$2M
Q3 25	$14M	$13M	$2M

Valuation

Quarter	P/S	P/E
Q4 22	6.2x	—
Q1 23	6.5x	—
Q2 23	6.6x	—
Q3 23	17.6x	—
Q4 23	11.0x	—
Q1 24	6.3x	—
Q2 24	4.1x	—
Q3 24	6.1x	—
Q4 24	7.5x	—
Q1 25	7.9x	—
Q2 25	3.8x	—
Q3 25	1.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$5M	-$5M
Q1 23	-$5M	-$5M
Q2 23	-$5M	-$5M
Q3 23	-$15M	-$15M
Q4 23	-$15M	-$15M
Q1 24	-$20M	-$20M
Q2 24	-$16M	-$16M
Q3 24	-$9M	-$9M
Q4 24	-$16M	-$16M
Q1 25	-$13M	-$13M
Q2 25	-$10M	-$10M
Q3 25	$10M	$10M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$66K
Q1 23	$11K
Q2 23	$59K
Q3 23	$65K
Q4 23	$227K
Q1 24	$0
Q2 24	$11K
Q3 24	$16K
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	-25.9%
Q1 23	-91.4%	-9.1%
Q2 23	-15.0%	+26.4%
Q3 23	-64.9%	+290.5%
Q4 23	+2823.5%	+300.1%
Q1 24	+10240.5%	+214.7%
Q2 24	+2744.5%	+72.8%
Q3 24	-161.1%	-29.5%
Q4 24	-82.7%	-53.2%
Q1 25	-10.1%	-48.4%
Q2 25	+145.4%	-45.1%
Q3 25	+905.4%	-32.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$1M	1722.1%
Q1 23	$1M	2956.8%
Q2 23	$2M	848.4%
Q3 23	$10M	331.3%
Q4 23	$2M	104.4%
Q1 24	$2M	54.2%
Q2 24	$2M	43.0%
Q3 24	$2M	—
Q4 24	$756K	219.8%
Q1 25	$1M	29.8%
Q2 25	$888K	7.0%
Q3 25	$718K	5.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$3M	$14M	—	—
Q1 23	$3M	$4M	—	—
Q2 23	$6M	$6M	—	—
Q3 23	$7M	$20M	—	—
Q4 23	$5M	$17M	$4K	—
Q1 24	$5M	$15M	$2M	—
Q2 24	$3M	$15M	$1M	—
Q3 24	$2M	$15M	$1M	—
Q4 24	$1M	$6M	$4M	—
Q1 25	$2M	$9M	$300K	—
Q2 25	$2M	—	—	$9M
Q3 25	$2M	—	—	$9M

Revenue Segments

Quarter	Collaboration	Product	License And Collaboration Revenue
Q3 23	$125K	$3M	—
Q1 24	$594K	$3M	—
Q2 24	$285K	$5M	—
Q4 24	$29K	$315K	—
Q1 25	$17K	$3M	—
Q2 25	—	$5M	$8M
Q3 25	—	$4M	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$34M	$0	$34M
Q1 23	$60M	$0	$60M
Q2 23	$55M	$0	$55M
Q3 23	$84M	$0	$84M
Q4 23	$70M	$0	$70M
Q1 24	$49M	$0	$49M
Q2 24	$32M	$0	$32M
Q3 24	$23M	$0	$23M
Q4 24	$46M	$0	$46M
Q1 25	$30M	$0	$30M
Q2 25	$15M	$0	$15M
Q3 25	$21M	$0	$21M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	4M	-8.0%
Q1 23	4M	+4.7%
Q2 23	5M	+6.7%
Q3 23	5M	+0.3%
Q4 23	5M	+0.5%
Q1 24	5M	+0.4%
Q2 24	5M	+0.0%
Q3 24	5M	+0.7%
Q4 24	7M	+43.8%
Q1 25	9M	+40.9%
Q2 25	9M	+0.1%
Q3 25	9M	-0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 16	—	—
FY 17	—	—
FY 18	$0	16
FY 19	$0	17
FY 20	$0	29
FY 21	$316K	38
FY 22	$411K	22
FY 23	$51K	100
FY 24	$107K	71